TG THERAPEUTICS, INC.
TGTXNasdaq
$54.87
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +41.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.8B
Enterprise Value
$9.0B
P/E
19.2
P/S
12.5
P/B
15.1
EV/EBITDA
60.3
PEG
—
FCF Yield
-0.2%
Dividend Yield
—
Revenue (TTM)
$700.3M
Net Income (TTM)
$461.9M
Free Cash Flow (TTM)
-$14.2M
Gross Margin
—
Operating Margin
21.3%
Net Margin
66.0%
ROE
79.2%
ROIC
18.4%
Debt / Equity
1.3
Net Cash
-$230.7M
Return 1Y
+40.0%
Company profile
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
- CEO
- Michael S. Weiss
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 290
- Headquarters
- New York
- Website
- tgtherapeutics.com
Earnings
TGTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$204.9M↑ +69.6%
Diluted EPS$0.12↑ +300.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $152,000.00 | $6.7M | $2.8M | $233.7M | $329.0M | $616.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$273.6M | -$344.8M | -$218.3M | $20.6M | $41.9M | $123.3M |
| Net income | — | -$348.1M | -$198.3M | $12.7M | $23.4M | $447.2M |
| Diluted EPS | -$2.42 | -$2.63 | -$1.65 | $0.09 | $0.15 | $2.77 |
| Operating cash flow | -$214.5M | -$295.6M | -$176.2M | -$31.4M | -$40.5M | -$24.8M |
| Free cash flow | -$214.9M | -$296.0M | -$176.2M | -$31.4M | -$40.6M | -$25.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -179996.1% | -5154.3% | -7839.0% | 8.8% | 12.7% | 20.0% |
| Net margin | — | -5204.1% | -7120.3% | 5.4% | 7.1% | 72.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.5M | $83.9M | $108.2M | $120.9M | $141.1M | $161.7M | $192.6M | $204.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $8.8M | $12.4M | $29.9M | $8.6M | $34.8M | $29.4M | $50.5M | $34.8M |
| Net income | $6.9M | $3.9M | $23.3M | $5.1M | $28.2M | $390.9M | $23.1M | $19.8M |
| Diluted EPS | $0.04 | $0.02 | $0.16 | $0.03 | $0.17 | $2.43 | $0.14 | $0.12 |
| Operating cash flow | $5.5M | -$12.2M | -$25.6M | -$28.7M | $7.4M | -$23.2M | $19.7M | -$17.9M |
| Free cash flow | $5.5M | -$12.2M | -$25.7M | -$28.7M | $7.4M | -$23.2M | $19.6M | -$17.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 12.0% | 14.8% | 27.7% | 7.1% | 24.7% | 18.2% | 26.2% | 17.0% |
| Net margin | 9.4% | 4.6% | 21.6% | 4.2% | 20.0% | 241.7% | 12.0% | 9.7% |
Company news
Jul 13, 2026
Jul 9, 2026
Jul 8, 2026
Jul 7, 2026
- 13d agoTGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launchstocktwits.com
- 13d agoModerna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Saysfinance.yahoo.com
- 13d agoTG Therapeutics Begins Phase II Study With Briumvi in Schizophreniafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-29 | Charney Laurence N | Gift | 13,197 | $0.00 | $0.00 | filing |
| 2026-01-28 | Charney Laurence N | Gift | 30,000 | $0.00 | $0.00 | filing |
| 2026-01-08 | WEISS MICHAEL S· CEO | Award | 622,000 | $0.00 | $0.00 | filing |
| 2026-01-08 | Power Sean A· CFO | Award | 90,000 | $0.00 | $0.00 | filing |
| 2025-11-24 | Echelard Yann | Sale | 5,000 | $32.57 | $162,850.00 | filing |
| 2025-11-05 | WEISS MICHAEL S· CEO | Gift | 3,865,126 | $0.00 | $0.00 | filing |
| 2025-11-05 | WEISS MICHAEL S· CEO | Gift | 803,717 | $0.00 | $0.00 | filing |
| 2025-09-11 | Lonial Sagar | Sale | 20,852 | $32.24 | $672,268.48 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.